Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Electronics Takes Step Into Korea's Biosimilar Foray With IND For MabThera Generic

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's electronics and semiconductor giant Samsung Electronics has submitted an investigational new drug application to Korea FDA to conduct clinical trials for its biosimilar of Roche's MabThera.
Advertisement

Related Content

Korea FDA OKs Samsung's Clinical Trial Application For Roche's MabThera Biosimilar
Korea FDA OKs Samsung's Clinical Trial Application For Roche's MabThera Biosimilar
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
Change Of Guard At Quintiles India As Company Continues Aggressive Asia Efforts With Samsung Deal
Samsung Electronics Takes Over Leading Medical Device Maker Medison
Samsung Electronics Takes Over Leading Medical Device Maker Medison
Roche Lashes Out At Biosimilars Regulations In Emerging Markets, Calls For Stricter Pharmacovigilance Of Launched Products
Korea's Celltrion Completes Phase I Clinical Trials For Biosimilars Based On Roche And Johnson & Johnson Products
Korean Court Upholds Employee Non-competition Clause In LG Contract; Puts Brakes On Samsung's Manhunt For Biosimilar Specialists
Advertisement
UsernamePublicRestriction

Register

SC076353

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel